Jessica L. Mega
Versar (United States)(US)
Publications by Year
Research Areas
Antiplatelet Therapy and Cardiovascular Diseases, Atrial Fibrillation Management and Outcomes, Lipoproteins and Cardiovascular Health, Acute Myocardial Infarction Research, Venous Thromboembolism Diagnosis and Management
Most-Cited Works
- → Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs(2016)7,251 cited
- → Cytochrome P-450 Polymorphisms and Response to Clopidogrel(2008)2,448 cited
- → Rivaroxaban in Patients with a Recent Acute Coronary Syndrome(2011)1,877 cited
- → Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI(2010)1,115 cited
- → Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update(2013)952 cited
- → Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy(2006)774 cited
- → Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials(2009)723 cited
- → Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials(2015)695 cited
- → Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel(2009)648 cited
- → Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis(2010)607 cited